Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;44:230-235
Published online before print July 12, 2004, doi: 10.1161/01.HYP.0000136751.04336.e9
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/2/230    most recent
01.HYP.0000136751.04336.e9v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez, J. A.
Right arrow Articles by Ferreri, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, J. A.
Right arrow Articles by Ferreri, N. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors

(Hypertension. 2004;44:230.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Bradykinin Regulates Cyclooxygenase-2 in Rat Renal Thick Ascending Limb Cells

Jorge A. Rodriguez; Carlos P. Vio; Paulina L. Pedraza; John C. McGiff; Nicholas R. Ferreri

From the Department of Physiology (J.A.R., C.P.V.), Pontificia Universidad Catolica de Chile, Santiago, Chile; and the Department of Pharmacology (P.L.P., J.C.M., N.R.F.), New York Medical College, Valhalla.

Correspondence to Carlos P. Vio, MD, Departamento de Ciencias Fisiologicas, Pontificia Universidad Catolica de Chile, Alameda 340, Santiago, Chile. E-mail cvio{at}bio.puc.cl


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cyclooxygenase-2 (COX-2) is constitutively expressed in a subset of thick ascending limb cells in the cortex and medulla and increases when the renin-angiotensin and kallikrein-kinin systems are activated. Although the contribution of angiotensin II to the regulation of COX-2 is known, the effects of bradykinin on COX-2 expression have not been determined in this nephron segment. We evaluated expression of B2 bradykinin receptors in thick ascending limb cells containing COX-2 and the effect of bradykinin on COX-2 expression in primary cultured medullary thick ascending cells. The presence of B2 receptors was studied in renal sections by immunohistochemistry with antibodies against B2, COX-2, and Tamm-Horsfall glycoprotein. B2 receptors were detected on the apical and basolateral portion of the thick ascending cells. These cells also contained COX-2, suggesting that COX-2 expression may be regulated via B2 receptor. Incubation of cultured medullary thick ascending cells with bradykinin (10–7 to 10–5 mol/L) induced a significant increase on COX-2 protein expression. Maximal expression of COX-2 was observed 4 hours after exposure to bradykinin (10–7 mol/L), effect abolished by a B2 receptor antagonist (HOE-140; 10–6 mol/L). Prostaglandin E2 production increased when these cells were challenged with bradykinin for 4 hours, indicating that COX-2 was enzymatically active. We have demonstrated (1) the presence of B2 receptors in thick ascending limb cells expressing COX-2 and (2) the stimulatory effect of bradykinin on COX-2 protein expression, via B2 receptors, in cultured medullary thick ascending cells. We suggest that bradykinin can affect ion transport in the thick ascending limb via a COX-2–mediated mechanism.


Key Words: cyclooxygenase • bradykinin • immunohistochemistry • rats • kidney • receptors, bradykinin • prostaglandins


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Prostaglandins participate in the regulation of the renal circulation1 and tubular ion transport as well as renin secretion, the latter via a cyclooxygenase-2 (COX-2)–dependent mechanism.2,3 The constitutive enzyme cyclooxygenase-1 (COX-1) has been identified in the collecting tubules and the renal vasculature.4,5 Immunohistochemical localization studies have detected COX-2 in the perimacula densa region and a subset of thick ascending limb (TAL) epithelial cells located in the cortex (cTAL)6,7 and outer medulla (mTAL)7 as well as in interstitial medullary cells.8 COX-2 expression in the kidney under basal conditions suggests that COX-2 may have a physiological role. Expression of the COX-2 isoform is increased in the kidney during development,9,10 adrenalectomy,11,12 and low-salt diet13; it is decreased by glucocorticoids.11,12

The kallikrein-kinin system (KKS)14 contributes to the regulation of renal blood flow and salt and water excretion. The renal effects of bradykinin under physiological conditions are mediated by the B2 receptor, whereas the B1 receptor is expressed in pathological states such as inflammation.15 Activation of the renin-angiotensin and KKS by administration of a low-sodium diet13 or angiotensin-converting enzyme inhibition16–19 increases renal COX-2 expression. The effects of angiotensin II (Ang II) on expression of COX-2 in the TAL segment via activation of Ang II type-1 receptors have been well documented, whereas the effects of bradykinin on renal COX-2 are unknown despite the identification of B2 receptors in this nephron segment.20 A biphasic response of the mTAL segment to Ang II, having a time-related dependency, has been characterized; namely, the initial response (0 to 4 hours) to Ang II is mediated by 20-HETE, the principal product of {omega} hydroxylase, a cytochrome P450 (CYP450) enzyme, whereas after 4-hour exposure to Ang II, COX-2 is expressed and prostaglandin E2 (PGE2) is produced in response to challenge by the peptide. We hypothesize that bradykinin, which has been linked to arachidonate product formation by both renal COX and CYP450,21,22 also regulates COX-2 expression in the TAL segment. Indeed, Grider et al20 have identified an early response by the rat mTAL to bradykinin similar to that of Ang II, namely receptor-mediated activation of a CYP450-dependent mechanism that inhibits NaCl reabsorption by the mTAL. Blockade of the bradykinin B2 receptor inhibited this effect of the peptide on the mTAL. Accordingly, we have addressed whether (1) bradykinin B2 receptors colocalize with TAL cells expressing COX-2, or (2) bradykinin acts through B2 receptors to stimulate COX-2 expression in mTAL cells.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Animals
The study was performed on adult male Sprague-Dawley rats (220 to 250 g for immunohistochemistry; 100 to 115 g for cell culture; n=26) maintained with free access to water and fed normal rat chow. The animals were purchased from and maintained at the Catholic University animal care facilities; experimental procedures were conducted in accordance with institutional and international guidelines for the welfare of animals (Animal Welfare Assurance #A5427–01, Office of Laboratory Animal Welfare, PHS, NIH). Surgery was performed under anesthesia with ketamine: xylazine (25:2.5 mg/kg, IP).

Antisera Chemicals and Peptides
Specific antibodies against murine COX-2 and against the bradykinin B2 receptor were used as previously described.7,10,23 Antiserum against Tamm-Horsfall glycoprotein, secondary antibodies, and peroxidase-antiperoxidase complexes were purchased from ICN Pharmaceuticals (Aurora, Ohio). Tissue culture media was purchased from Life Technologies (Grand Island, NY); bradykinin and the B1 receptor antagonist Des-Arg-Leu8-bradykinin and chemicals were purchased from Sigma (St. Louis, Mo). The B2 receptor antagonist HOE-140 was a gift from Hoechst (Frankfurt, Germany).

Tissue Processing and Immunohistochemistry
Renal slices including cortex, medulla, and papilla were fixed in Bouin’s fixative and processed as described.12 The localization of B2 receptor and COX-2 protein was evaluated by immunohistochemistry, and the cellular origin of B2 receptors was assessed by double immunolabeling for B2 receptors and Tamm-Horsfall glycoprotein (a specific marker for TAL cells) in the same tissue sections. The double immunolabeling was performed as previously described.12 Briefly, the first antibody immunostaining was developed with diaminobenzidine-hydrogen peroxide to give a brown color, whereas the following primary antibody, immunostaining was developed with Vector SG substrate to give a blue color. Appropriate immunostaining controls were done as described.12 The sections were observed and photographed on a Nikon Eclipse 600 microscope with a Nikon DXM1200 digital camera.

Isolation of mTAL Cells
The isolation and characterization of mTAL cells were performed as previously described.24 Briefly, kidneys were removed, and the outer medulla was excised and incubated in collagenase solution. The supernatant of the suspension was collected, spun, resuspended in Hank’s solution, and filtered through a 52-µm nylon mesh membrane. The tubules retained on the mesh were resuspended, and the cells were cultured. Cells at 80% confluence were made quiescent for 24 hours before their use.

The Western blot was performed as previously described.24 The proteins from cell lysates were separated on a 10% SDS-PAGE gel and transferred to PVDF membranes, immunoblotted with either a rabbit anti-COX-2 polyclonal antibody (Cayman Chemicals, Ann Arbor, Mich) or rabbit anti-extracellular signal regulated kinase (ERK)2 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, Calif), and incubated horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence was used to evaluate protein expression. The blots were scanned, and densitometric analysis was performed using the public domain NIH Image program v1.61 (US National Institutes of Health, http://rsb.info.nih.gov/nih-image). The expression of ERK2 was used to correct for variation in sample loading.

PGE2 ELISA
Quiescent mTAL cells were incubated with bradykinin (10–7mol/L) in RPMI 1640 containing 0.5% serum for varying times. Cell-free supernatants were assayed for PGE2 by ELISA (Neogen) according to the protocol provided by the manufacturer.

Statistical Analysis
The differences were assessed with the nonparametric test of Mann-Whitney. Data are presented as mean±SEM; P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Localization of COX-2 in cTAL and mTAL Segments
COX-2 protein expression was observed in small and scattered groups of cells belonging to the TAL located in the cortex and outer medulla (Figure 1a and 1b). The cells displaying COX-2 were heavily stained, compared with unstained neighboring tubular cells. The schematic diagram in Figure 1 indicates the relationship between the localization of an arcuate artery and a juxtamedullary nephron as shown in Figure 1b. Because the arcuate artery defines the boundaries between the cortex and the outer medulla, the TAL segment containing COX-2 in the medulla corresponds to juxtamedullary nephrons, whereas those present in the cortex belong to cortical nephrons (Figure 1a and 1b). No immunostaining was observed in glomeruli, proximal tubules, or collecting ducts.



View larger version (82K):
[in this window]
[in a new window]
 
Figure 1. Immunohistochemical localization of COX-2 in renal sections. Note the small number of TAL cells containing COX-2 (brown; a). TAL belonging to cortical and juxtamedullary nephrons expresses COX-2. The division of cortex and outer medulla is identified by the presence of the arcuate artery (arrow; b). The illustration shows the anatomy of the medulla and the length of the TAL between the cortical and juxtamedullary nephrons (b). The dotted line indicates the outer medulla, which is comprised mainly of mTAL cells (see Methods). The inserts show TAL cells containing COX-2 in high magnification. * Glomeruli. Scale bar=100 µm. (Scheme of the nephron reprinted with permission from Kriz W. Structural organization of the renal medulla: comparative and functional aspects. Am J Physiol. 1981;241:R3–R16.).

Colocalization of B2 Receptors and COX-2 in the TAL
The immunostained renal tissue revealed the presence of B2 receptors in the TAL, connecting tubule, and collecting duct. The presence of B2 receptors was observed in the apical and in the basolateral portions of TAL cells (Figure 2). Double label immunolocalization confirmed the expression of B2 receptors in TAL as demonstrated by Tamm-Horsfall glycoprotein with the bradykinin B2 receptors (Figure 3a and 3b). COX-2 positive cells also expressed the B2 receptor on both cellular sides (Figure 3c and 3d) although B2 receptors were detected on COX-2 positive as well as negative cells. These data indicate that in subsets of TAL cells, a close association exists between components of the KKS and prostaglandin systems. Nearly all mTAL cells in culture expressed Tamm-Horsfall glycoprotein (95%) (Figure 3e and 3f); however, only few mTAL cells ({approx}5%) expressed COX-2 displayed in the cytoplasmatic and perinuclear regions (Figure 3f). No staining was observed with immunostaining controls.



View larger version (154K):
[in this window]
[in a new window]
 
Figure 2. Immunohistochemical localization of B2 receptors in renal sections. The B2 receptor was observed in the thick ascending limb. Higher magnification shows the subcelular distribution of B2 receptors in the apical and basolateral sides (arrows). Scale bar=100 µm.



View larger version (144K):
[in this window]
[in a new window]
 
Figure 3. Localization of B2 receptors and colocalization with COX-2 along the TAL. Using double label immunohistochemistry, the presence of B2 receptors (brown) was observed in TAL cells identified by the presence of Tamm-Horsfall glycoprotein (blue; a, b). Cells immunoreactive for COX-2 (blue) expressed bradykinin B2 receptors (brown; c, d). mTAL cells in culture were identified by the presence of Tamm-Horsfall glycoprotein (e). Some of the cells display immunoreactivity to COX-2 within the cytoplasm (brown arrow; f). Scale bar=50 µm.

Bradykinin Increases COX-2 Expression in mTAL Cells
Western blot analysis of cellular extracts was performed to determine the effects of bradykinin on COX-2 expression by cultured mTAL cells. COX-2 protein increased significantly after exposure to concentrations of bradykinin of ≥10–7 mol/L (Figure 4). The nearly 2-fold increase in COX-2 expression was transient, peaked at 4 hours, and gradually decreased from 8 to 48 hours (Figure 5). Thus, bradykinin increased COX-2 expression by mTAL cells in a time- and concentration-dependent manner.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 4. Effects of bradykinin on COX-2 expression by mTAL cells in culture. Bradykinin (10–7 mol/L) increased COX-2 in mTAL cells. Data represent the mean±SEM of the intensities of bands determined by densitometry and normalization with ERK2. * Different from control, P<0.05; n=3. Insert shows a representative Western blot.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 5. Effects of bradykinin on COX-2 expression by mTAL cells in culture are time dependent. COX-2 protein expression in mTAL cells challenged with bradykinin (10–7 mol/L) increases at 2, 4, 8, and 24 hours returning to control value at 48 hours. Data represent the mean±SEM of the intensities of bands determined by densitometry and normalization with ERK2. * Different from control, P<0.05; n=3. Insert shows a representative Western blot.

Preincubation with a selective B2 receptor antagonist (HOE-140, 10–6 mol/L), but not a B1 receptor antagonist (Des-Arg-Leu8-bradykinin; 10–6 mol/L), abolished the stimulatory effect of bradykinin on COX-2 protein expression (Figure 6). To evaluate if the COX-2 protein induced by bradykinin was enzymatically active, mTAL cells were challenged with bradykinin (10–7 mol/L) and PGE2 production was measured by ELISA. Bradykinin caused a transient increase in PGE2 synthesis (1.7-fold of control, 10.3±0.8 pg/µg protein) at 4 hours (Figure 7).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 6. Effect of bradykinin on COX-2 expression is B2-mediated. mTAL cells preincubated (30 minutes) in the presence or absence of B1 (Des-Arg-Leu8-Bradykinin; 10–6mol/L) or B2 (HOE-140; 10–6mol/L) receptor antagonists were challenged with bradykinin (10–7mol/L) for 4 hours. The results demonstrate that the effect of bradykinin is B2-mediated. Data represent the mean±SEM of the intensities of bands determined by densitometry and normalization with ERK2. * Different from control, P<0.05. + Different from bradykinin, P<0.05; n=3. Insert shows a representative Western blot.



View larger version (10K):
[in this window]
[in a new window]
 
Figure 7. Effect of bradykinin on PGE2 production. Incubation of bradykinin (10–7 mol/L) for 4 hours significantly increases PGE2 production in cultured mTAL cells. PGE2 levels were determined by enzyme-linked immunoassay in cell-free supernatants. Data represent the mean±SEM. * Different from control, P<0.05; n=3.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
We have demonstrated that COX-2 protein is constitutively expressed in a small percentage ({approx}5%) of cTAL and mTAL cells in vivo as well as in cultured mTAL cells. B2 receptors were detected in the collecting ducts and connecting tubules, and to the apical and basolateral portions of TAL cells. Colocalization studies revealed that subsets of TAL cells can be identified based on the differential expression of B2 and COX-2. Namely, TAL cells expressing B2 can be sorted as either B2(+)/COX-2(+) or B2(+)/COX-2(–). Human podocytes also have been described to express COX-225 and B2 receptors.26 Bradykinin, via a B2-dependent mechanism, increased COX-2 protein expression that was enzymatically active as it metabolized endogenous arachidonic acid to PGE2. Bradykinin also induced COX-2 expression in human airways and pulmonary artery smooth muscle cells27,28 and potentiated COX-2 mRNA accumulation in fibroblasts,29 human endothelial cells,30 and leptomeninges.31 It is important to note that, although the in vivo expression of COX-2 in the cTAL has been well described, the present study also demonstrates the expression of COX-2 in mTAL cells in vivo. A recent publication also has demonstrated constitutive in vivo expression of COX-2 in the mTAL.32

The immunohistochemical results are in agreement with previous observations restricting COX-2 to a subset of TAL cells. The heterogeneous expression of COX-2 in this nephron segment is consistent with the existence of a subpopulation of TAL cells. TAL heterogeneity, reported by Allen and Tisher,33 described rough and smooth surface subtypes of cells. More recently, differential expression of renal outer medullary K+ (ROMK) channels34 and H+, K+-ATPase35 were demonstrated in this nephron segment. However, the complete phenotype of TAL subsets and the potential role for functional diversity have not been clarified. Bradykinin B2 receptors were expressed on both apical and basolateral sides of TAL cells of normal rats. In addition to the TAL, B2 receptors are expressed in connecting tubules and collecting ducts,36,37 providing an anatomical basis for involvement of this tubular segment in the renal actions of the KKS and its contribution to the regulation of salt and water excretion. In the present study, the localization of B2 receptors along the TAL was performed by a colocalization method to identify the Tamm-Horsfall glycoprotein, a specific marker of the TAL. Expression of B2 receptors was detected in apical and basolateral membranes of TAL cells more apically concentrated, whereas previous reports described similar receptor expression on both sides.36,37 Expression of the B2 receptor in both cell sides may explain the asymmetric function of bradykinin described in different nephron segments. Bradykinin when added only to the apical surface of the collecting duct cells caused PGE2 release,38 whereas bradykinin added to the basolateral side significantly inhibited chloride transport in mTAL.20 We conclude that the renal effects of bradykinin are dependent, at least in part, to activation of B2 receptors in TAL cells.

COX-2 is not restricted to cortical nephrons as it is also expressed in juxtamedullary nephrons that extend into the medulla. Owing the important contribution of juxtamedullary nephrons to ion transport and to the osmolar gradient required for concentrating urine, we focused on the mTAL cells in culture where we demonstrated bradykinin-inducible, enzymatically active COX-2 protein. COX-2 activity was demonstrated by increased PGE2, the main prostaglandin secreted in TAL,39 in the nephron segment, where its specific synthase is localized.40 We have shown41 that Ang II on stimulating tumor necrosis factor production by the mTAL can cause COX-2 expression after a delay of 3 to 4 hours. The immediate response to Ang II of freshly isolated mTAL tubules is production of 20-HETE via {omega} hydroxylase present in mTAL segments in situ. A similar effect to Ang II has been reported for bradykinin; namely, bradykinin (like Ang II) inhibits mTAL transport function by stimulating production of 20-HETE. It should be noted that cultured mTAL cells lose their capacity to express CYP450 enzyme activity42; the latter is superceded by COX-2 when cells are cultured.41 Activation of the calcium-sensing receptor also increased COX-2 expression in mTAL cells.43 Moreover, recruitment of COX-2 containing cells in the mTAL has been reported to occur during development9,10,44 or in response to decreased secretion of corticosteroids by adrenalectomy.12,44 In each instance, COX-2 expression is observed in an orderly manner proceeding from cortex to outer medulla, indicating that mTAL cells, in addition to cTAL cells, retain the capacity to express COX-2.

The B1 receptor is inducible and is expressed in pathological conditions, whereas the B2 receptor is constitutive and participates in physiological functions of the kidney. The stimulatory effect of bradykinin on COX-2 expression was abolished by a B2 receptor antagonist. The effect of B2 but not B1 receptors on COX-2 regulation is consistent with significant contributions of COX-2–derived prostaglandins to transport functions of the TAL segment under physiological conditions. The regulation of COX-2 expression by bradykinin in the TAL segment may help to explain the effects of bradykinin on salt and water regulation.45 Thus, it required inhibition of both isoforms of COX (COX-1 and COX-2) in addition to inhibition of nitric-oxide synthase to prevent the excretory actions of bradykinin, suggesting that the natriuretic action of bradykinin requires the participation of both COX-1 and COX-2 as well as NO.

Perspectives
This study suggests a potential role for bradykinin on transport function in a key tubular segment, the mTAL, by virtue of controlling expression and activity of COX-2. We propose that the production of PGE2 by the TAL via induction of COX-2 in response to kinin stimulation of B2 receptors contributes to regulation of extracellular fluid volume and blood pressure.


*    Acknowledgments
 
This work was part of the PhD degree requirements for J.A.R. This work was supported by a Grant Fondecyt1010373, and a doctoral fellowship from Comision Nacional de Investigacion Cientifica y Tecnologica (J.A.R.). This investigation was also supported by a National Institutes of Health Fogarty International Research Collaboration Award (TW001115–03; N.R.F., C.P.V.) and National Institutes of Health PPG-HL34300 (J.C.M., N.R.F.). The technical assistance of Maria Alcoholado and Carlos Cespedes are acknowledged.

Received January 30, 2004; first decision February 20, 2004; accepted June 11, 2004.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol. 2000; 279: F965–F981.

2. Traynor T, Smart A, Briggs J, Schnermann J. Inhibition of macula densa-stimulated renin secretion by pharmacology blockade of cyclooxygenase-2. Am J Physiol. 1999; 277: F706–F710.[Medline] [Order article via Infotrieve]

3. Castrop H, Schweda F, Schumacher K, Wolf K, Kurtz A. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol. 2001; 12: 867–874.[Abstract/Free Full Text]

4. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol. 1978; 235: F451–F457.[Medline] [Order article via Infotrieve]

5. Campean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol. 2003; 285: F19–F32.

6. Harris R, McKanna J, Akai Y, Jacobson H, Dubois R. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504–2510.[Medline] [Order article via Infotrieve]

7. Vio CP, Cespedes C, Gallardo P, Masferrer J. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension. 1997; 30: 687–692.[Abstract/Free Full Text]

8. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol. 1998; 26: 612–620.[Abstract/Free Full Text]

9. Zhang MZ, Wang JL, Cheng HF, Harris R, McKanna J. Cyclooxygenase-2 in rat nephron development. Am J Physiol. 1997; 273: F994–F1002.[Medline] [Order article via Infotrieve]

10. Vio CP, Balestrini C, Recabarren M, Cespedes C. Postnatal development of cyclooxygenase-2 in the rat kidney. Immunopharmacol. 1999; 44: 205–210.[CrossRef][Medline] [Order article via Infotrieve]

11. Zhang M, Harris R, McKanna J. Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc Natl Acad Sci U S A. 1999; 96: 15280–15285.[Abstract/Free Full Text]

12. Vio CP, An SJ, Cespedes C, McGiff JC, Ferreri NR. Induction of cyclooxygenase-2 in thick ascending limb cells by adrenalectomy. J Am Soc Nephrol. 2001; 12: 649–658.[Abstract/Free Full Text]

13. Yang T, Pham S, Sun D, Smart A, Schnermann J, and Briggs J. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol. 1998; 274: F481–F489.[Medline] [Order article via Infotrieve]

14. Vio CP, Loyola S, Velarde V. Localization of components of the kallikrein-kinin system in the kidney: relation to renal function. Hypertension. 1992; (suppl 2): 19: II-10–II-16.[Medline] [Order article via Infotrieve]

15. Couture R, Harrison M, Vianna Clotier F. Kinin receptors in pain and inflammation. Eur J Pharmacol. 2001; 429: 161–176.[CrossRef][Medline] [Order article via Infotrieve]

16. Cheng HF, Wang JL, Zhang MZ, Iyazaki Y, Ichikawa I, McKanna J, Harris R. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest. 1999; 103: 953–961.[Medline] [Order article via Infotrieve]

17. Wolf K, Castrop H, Hartner A, Goppelt-Strübe M, Hilgers K, Kurtz A. Inhibition of the renin-angiotensin upregulates cyclooxygenase-2 expression in the macula densa. Hypertension. 1999; 34: 503–507.[Abstract/Free Full Text]

18. Kammerl M, Richthammer W, Kurtz A, Krämer B. Angiotensin II feedback is a regulator of renocortical renin, COX-2, and nNOS expression. Am J Physiol. 2002; 282: R1613–R1617.

19. Castrop H, Klar J, Wagner C, Höcherl K, Kurtz A. General inhibition of renocortical cyclooxygenase-2 by the renin-angiotensin system. Am J Physiol. 2003; 284: F518–F524.

20. Grider J, Falcone J, Kilpatrick E, Ott C, Jackson B. Effect of bradykinin on NaCl transport in the medullary thick ascending limb of the rat. Eur J Pharmacol. 1995; 287: 101–104.[CrossRef][Medline] [Order article via Infotrieve]

21. McGiff JC, Terragno NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res. 1972; 31: 36–44.[Abstract/Free Full Text]

22. Fulton D, McGiff JC, Quilley J. Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol. 1992; 107: 722–725.[Medline] [Order article via Infotrieve]

23. Vio CP, Velarde V, Müller-Esterl W. Cellular distribution and fate of the bradykinin antagonist HOE-140 in the rat kidney. Colocalization with the bradykinin B2 receptor. Immunopharmacol. 1996; 33: 146–150.[CrossRef][Medline] [Order article via Infotrieve]

24. Ferreri NR, An SJ, McGiff JC. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am J Physiol. 1999; 277: F360–F368.[Medline] [Order article via Infotrieve]

25. Kömhoff M, Grone HJ, Kein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and –2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997; 272: F460–F468.[Medline] [Order article via Infotrieve]

26. Ardaillou N, Blaise V, Costenbader K, Vassitch Y, Ardaillou R. Characterization of B2-bradykinin receptor in human glomerular podocytes. Am J Physiol. 1996; 271: F754–F761.[Medline] [Order article via Infotrieve]

27. Pang L, Knox A. PGE2 release by bradykinin in human airway smooth muscle cells: involvement of cyclooxygenase-2 induction. Am J Physiol. 1997; 273: L1132–L1140.[Medline] [Order article via Infotrieve]

28. Bradbury DA, Newton R, Zhu YM, Stocks J, Corbett L, EDHolland, Pang LH, Knox AJ. Effect of bradykinin, TGF-ß1, IL-1ß and hypoxia on COX-2 expression in pulmonary artery smooth muscle cells. Am J Physiol. 2002; 283: L717–L725.

29. Nakao S, Ogata Y, Modéer T, Segawa M, Furuyama S, Sugiya H. Bradykinin induces a rapid cyclooxygenase-2 mRNA expression via Ca2+ mobilization in human gingival fibroblast primed with interleukin-1ß. Cell Calcium. 2001; 29: 446–452.[CrossRef][Medline] [Order article via Infotrieve]

30. Gryglewski R, Chlopicki S, Uracz W, Marcinkiewicz E. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation. Med Sci Monit. 2001; 7: 1–16.[Medline] [Order article via Infotrieve]

31. Brian J, Faraci F, Moore F. COX-2 dependent delayed dilatation of cerebral arterioles in response to bradykinin. Am J Physiol. 2001; 280: H2023–H2029.

32. Nasrallah R, Landry A, Singh S, Sklepowicz M, Hébert R. Increased expression of cyclooxygenase-1 and –2 in the diabetic rat renal medulla. Am J Physiol. 2003; 285: F1068–F1077.

33. Allen F, Tisher C. Morphology of the ascending limb of Henle. Kidney Int. 1976; 9: 8–22.[Medline] [Order article via Infotrieve]

34. Ecelbarger C, Kim G, Knepper M, Liu J, Tate M, Welling P, Wade J. Regulation of potassium channel kir 1.1 (ROMK) abundance in the thick ascending limb of Henle’s loop. J Am Soc Nephrol. 2001; 12: 10–18.[Abstract/Free Full Text]

35. Verlander J, Moudy R, Campbell G, Cain B, Wingo C. Immunohistochemical localization of H,K-ATPase {alpha}2C-subunit in rabbit kidney. Am J Physiol. 2001; 281: F357–F365.

36. Figueroa C, Gonzalez C, Grigoriev S, Alla SA, Haasemann M, Jarnagin K, Müller-Esterl W. Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies. J Hystochem Cytochem. 1995; 43: 137–148.

37. El-Dahr S, Figueroa C, González C, Müller-Esterl W. Ontogeny of bradykinin B2 receptors in the rat kidney: implications for segmental nephron maturation. Kidney Int. 1997; 51: 739–749.[Medline] [Order article via Infotrieve]

38. Garcia-Perez A, Smith W. Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. J Clin Invest. 1984; 74: 63–74.[Medline] [Order article via Infotrieve]

39. Farman N, Pradelles P, Bonvalet J. PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 synthesis along the rabbit nephron. Am J Physiol. 1987; 252: F53–F59.[Medline] [Order article via Infotrieve]

40. Campean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol. 2003; 285: F19–F32.

41. Ferreri NR, Escalante BA, Zhao Y, An SJ, McGiff JC. Angiotensin II induces TNF production by the thick ascending limb: functional implications. Am J Physiol. 1998; 274: F148–F155.[Medline] [Order article via Infotrieve]

42. Drugge ED, Carroll MA, McGiff JC. Cells in culture from rabbit medullary thick ascending limb of Henle’s loop. Am J Physiol. 1989; 256: C1070–C1081.[Medline] [Order article via Infotrieve]

43. Wang D, An SJ, Wang W, McGiff JC, Ferreri NR. CaR-mediated COX-2 expression in primary cultured mTAL cells. Am J Physiol. 2001; 281: F658–F664.

44. Leon CG, Marchetti J, Vio CP. Renal cyclooxygenase-2: evidence for recruitment of thick ascending limb of henle cells in microdissected nephron segments. Hypertension. 2001; 38 (suppl 3, pt 2): 630–634.[Abstract/Free Full Text]

45. Rodriguez F, Llinas M, Moreno C, Salazar J. Role of Cyclooxygenase-2-derived metabolites and NO in renal response to bradykinin. Hypertension. 2001; 37: 129–134.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
B. Eng, S. Mukhopadhyay, C. P. Vio, P. L. Pedraza, S. Hao, S. Battula, P. B. Sehgal, J. C. McGiff, and N. R. Ferreri
Characterization of a long-term rat mTAL cell line
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1413 - F1422.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M.-Z. Zhang, B. Yao, H.-F. Cheng, S.-W. Wang, T. Inagami, and R. C. Harris
Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT1 and AT2 receptors
PNAS, October 24, 2006; 103(43): 16045 - 16050.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. A. Rodriguez, P. De la Cerda, E. Collyer, V. Decap, C. P. Vio, and V. Velarde
Cyclooxygenase-2 induction by bradykinin in aortic vascular smooth muscle cells
Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H30 - H36.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/2/230    most recent
01.HYP.0000136751.04336.e9v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez, J. A.
Right arrow Articles by Ferreri, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez, J. A.
Right arrow Articles by Ferreri, N. R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow ACE/Angiotension receptors